site:imx.to — Yandex:found 40 thousand results
{"2_iyaz":{"state":{"form":{"action":"/search","searchLabel":"Search","hiddenInputs":[{"name":"lr","value":21206}],"logo":{"href":"//yandex.com","isForeign":true ...
Immix Bio：组织特异性多激酶抑制剂公司申请IPO上市 - 雪球
2021年9月27日 · imx-110通过阻断多种激酶，干扰nf-κb 和stat3活化，阻断炎症周期中的正反馈循环，阻断肿瘤持续性炎症。 IMX-110目前处在临床1b/2a期，开发指征为软肉瘤，截止2021 …
SEC.gov | HOME
The U.S. Food and Drug Administration (“FDA”) has approved orphan drug designation (“ODD”) for IMX-110 for the treatment of soft tissue sarcoma. The FDA has already approved rare …
Immix Biopharma Announces Early Positive IMX-110 Interim
2023年5月3日 · IMMINENT-01 is a first-of-its-kind, ongoing phase 1b/2a clinical trial combining tissue specific therapeutic IMX-110 with BeiGene / Novartis’ anti-PD-1 antibody tislelizumab, in …
Immix reports positive interim results from cancer therapy trial
2023年5月4日 · Immix Biopharma has reported early positive interim data from its ongoing Phase Ib/IIa dose escalation clinical trial IMMINENT-01 of IMX-110 for the treatment of advanced …
Immix Biopharma's IMX-110 / Anti-PD-1 Combo Therapy Shows …
2022年1月25日 · Immix Biopharma Inc's (NASDAQ: IMMX) IMX-110 + anti-PD-1 produced 63-day median survival in a genetic pancreatic cancer mouse model, in which mice develop their own …
Immix Biopharma Announces Early Positive IMX-110 Interim …
2023年5月3日 · Immix Biopharma Announces Early Positive IMX-110 Interim Clinical Trial Data Demonstrating 100% Tumor Shrinkage in Advanced Metastatic Colorectal Cancer at the …
curcumin/doxorubicin (iMX-110) / Immix Biopharma - LARVOL
Fabrication of curcumin-loaded nano-micelles based on quercetin-quarternary ammonium-chitosan (Qu-QCS) conjugate and evaluation of synergistic effect with doxorubicin against …
Immix Biopharma — IMX-110 interim results in colorectal cancer
2023年7月19日 · Immix Biopharma is developing a new class of tissue-specific therapeutics targeting oncology and immune-dysregulated disease. Its lead asset, IMX-110, is being …
Immix Biopharma Announces Dosing of First 2 Patients in its IMX …
2023年2月7日 · IMX-110 + Beigene/Novartis anti-PD-1 Tislelizumab combination designed to enhance response to solid tumors by turning immunologically “cold” tumors “hot”Initial data …